Related Experiment Videos
Peripheral blood cells transplantation--a review article
1Department of Haematology, Institute of Postgraduate Medicine & Research, Dhaka.
Bangladesh Medical Research Council Bulletin
|April 12, 2000
Summary
Blood and cancer treatment (BCT) has advanced significantly, offering effective, less costly, and faster recovery. These techniques may enable new high-dose chemotherapy regimens and adoptive immunotherapy for better cancer treatment outcomes.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Twelve years of advancements in Blood and Cancer Treatment (BCT) techniques.
- BCT offers improved efficacy, reduced cost, faster recovery, and shorter hospital stays.
- Potential for high-dose chemotherapy and novel antitumor drugs previously limited by toxicity.
Purpose of the Study:
- To review the advancements in Blood and Cancer Treatment (BCT) techniques.
- To explore the potential of BCT in treating hematological malignancies.
- To discuss the role of BCT in adoptive immunotherapy and minimal residual disease treatment.
Main Methods:
- Review of published data on Blood and Cancer Treatment (BCT) over the past twelve years.
- Analysis of the impact of BCT on chemotherapy, drug development, and patient outcomes.
- Exploration of ex-vivo selection and expansion of immune effector cells for immunotherapy.
Main Results:
- BCT techniques are now easier to perform, more effective, and less costly.
- BCT allows for rapid hematological recovery, reduced morbidity and mortality.
- Potential for treating hematological malignancies with purged autologous or manipulated allogeneic cells.
Conclusions:
- BCT shows promise for adoptive immunotherapy and treating minimal residual disease (MRD).
- Discovery of engraftment facilitator cells may improve GVHD prevention and immunotherapy.
- BCT is likely to supersede Bone Marrow Transplantation (BMT), pending longer follow-up.